Login
Communauté Vinci
Extérieur
Si votre nom d'utilisateur ne se termine pas par @vinci.be ou @student.vinci.be, utilisez le formulaire ci-dessous pour accéder à votre compte de lecteur.
Titre : | Efficacy of Kanglaite against radiotherapy-induced mucositis in head and neck cancer, a phase II trial (2022) |
Auteurs : | Z.-P. Liu ; Q.-Y. Song ; C.-L. Chu ; S.-H. Liu ; Y.-X. Ren ; J. Chen ; Daxin Zhang |
Type de document : | Article |
Dans : | Cancer/Radiothérapie (vol. 26, no. 4, Juin 2022) |
Article en page(s) : | p. 585-593 |
Note générale : | https://doi-org.ezproxy.vinci.be/10.1016/j.canrad.2021.11.024 |
Langues: | Anglais |
Descripteurs : |
HE Vinci Mucite ; Radiothérapie ; Tumeurs de la tête et du cou |
Mots-clés: | Kanglaite |
Résumé : | Purpose To explore the potential protective effect of Kanglaite injection against radiotherapy-induced mucositis in patients with head and neck cancer. Patients and methods This was an open-label, single-arm, and phase II trial. The primary endpoint was the incidence of grade 3?4 radiation-induced mucositis. The secondary endpoints were hematological toxicity, non-hematological toxicity, nutritional status, and quality of life. All patients received 20g Kanglaite daily concurrently with radiotherapy. Results The data of 46 patients were available for analysis. The incidence rates of grade 3 mucositis, pain, dysphagia, and neutropenia were 10.9%, 2.2%, 10.9%, and 6.5%, respectively, while the incidence of grade 4 acute toxicities was zero. The rate of opioid use was 2.2%. Radiotherapy dose reduction was 2.2% and no irradiation field was modified. The nutritional supports were oro-enteral nutritional supplements (13.0%), TPN (10.9%), and feeding tubes (0%) during radiotherapy. After radiotherapy, 52.2% of patients lost weight, and the weight loss was |
Disponible en ligne : | Oui |
En ligne : | https://login.ezproxy.vinci.be/login?url=https://www.sciencedirect.com/science/article/pii/S1278321822000269 |